DS BIOPHARMA LTD has a total of 37 patent applications. It increased the IP activity by 16.0%. Its first patent ever was published in 2010. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are NEUROTECH PHARMACEUTICALS CO LTD, MACGREGOR ALEXANDER and CT LAB INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 15 | |
#2 | EPO (European Patent Office) | 9 | |
#3 | Australia | 3 | |
#4 | Japan | 3 | |
#5 | Israel | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Canada | 1 | |
#8 | China | 1 | |
#9 | Hungary | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Coughlan David | 25 |
#2 | Manku Mehar | 24 |
#3 | Climax John | 21 |
#4 | Dunne James | 14 |
#5 | Kelliher Adam | 7 |
#6 | Morrison Angus | 7 |
#7 | Knowles Phil | 7 |
#8 | Downes Bill | 4 |
#9 | Mehar Manku | 3 |
#10 | David Coughlan | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020079250A1 | Dgla and/or 15-hetre for treating inflammatory, fibrotic, and proliferative conditions | |
US2018333382A1 | Pharmaceutical compositions comprising dgla and use of same | |
EP3399971A1 | Pharmaceutical compositions comprising dgla and use of same | |
EP3546446A1 | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids |